Thermo Fisher Collaborates with NX Prenatal to Develop Proteomics Assays for Adverse Pregnancy Outcomes
Shots:
- Thermo Fisher and NX Prenatal enter into a collaboration to develop proteomics assays by combining NX Prenatal's NeXosome platform with Thermo Fisher's LC-MS instrumentation for monitoring the maternal & fetal health and evaluating the risk of complications
- The focus of the collaboration is to provide a diagnostic solution to both clinical and medical professionals by evaluating maternal and fetal biomarkers during pregnancy and to assess adverse outcomes including preterm birth and preeclampsia for improving health
- NX Prenatal's NeXosome technology harvest microparticles (exosomes) from the mother’s blood- maintaining the balance between mother & fetus during the pregnancy
Ref: Thermo Fisher | Image: Evaluating Pharma
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com